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Background: Understanding factors associated with high placebo responses in clinical trials 
increases the likelihood of detecting a meaningful treatment effect. The aim of the present 
study was to identify subject-level factors that contribute to placebo variability in patients with 
neuropathic pain due to spinal cord injury (SCI).
Methods: Multiple regression analysis of patient data from randomized, double-blind, placebo-
controlled trials (duration >4 weeks) involving individuals with SCI was performed. Patient 
demographics, as well as injury and pain characteristics were examined for their association 
with changes in pain rating from baseline to the end of the trial (i.e., placebo response). The 
overall effect of individual predictors was quantified with meta-analysis statistics.
Results: A total of 276 patients with SCI from six studies were included in the analysis. Based on 
the meta-analysis of subject-level predictors, larger placebo responses were associated with male 
subjects (β=0.635; standard error [SE]=0.262; p=0.016) and higher baseline pain (β=−0.146; 
SE=0.073; p=0.044). There were no significant effects for injury characteristics (i.e., severity, 
level, and time since injury) or pain characteristics (i.e., location and evoked). No significant 
publication bias was detected.
Conclusion: The current meta-analysis of individual patient data demonstrated the importance 
of sex and baseline pain intensity on changes in pain ratings in the placebo arm of SCI central 
neuropathic pain randomized controlled clinical trials. Overall, our findings indicate that placebo 
responses occur independent of injury characteristics.
Keywords: placebo response, clinical trial, spinal cord injury, neuropathic pain
Introduction
The placebo effect represents a major challenge for the design of clinical trials aimed 
at relieving chronic pain. The difficulty stems from large changes in pain without an 
active intervention, which potentially masks meaningful treatment effects. The “pla-
cebo problem” is compounded by limited prediction of treatment effects based on 
preclinical pain models.1–3 Understanding factors underlying placebo responses has, 
as a consequence, emerged as an approach to improve the design and interpretation 
of chronic pain clinical trial outcomes.4–7
Central neuropathic pain arises because of damage in the central nervous system 
(CNS), and is common in individuals with multiple sclerosis, stroke, and spinal cord 
injury (SCI).8–10 Interestingly, clinical trials in SCI neuropathic pain report smaller 
placebo responses relative to other neuropathic pain conditions (e.g., diabetic and 
HIV neuropathy).11 This difference raises the possibility that unique factors  associated 
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with central neuropathic pain (e.g., damage in the CNS) 
contribute to lower placebo responses. A recent meta-
analysis identified that longer pain duration and greater 
between-subject baseline pain variability were associated 
with a decreased placebo response in patients with central 
neuropathic pain.12
Meta-analyses of published studies are often used to 
pool effect sizes.13,14 As an extension of meta-analysis, 
meta-regression is commonly performed to examine the 
relationship between effect size and study (e.g., sample size 
and allocation concealment) and patient-level variables (e.g., 
age and sex). Conventional meta-regression of pooled study 
data suffers from major limitations. The most substantial 
concern is that a correlation observed at the study level may 
be inversely correlated at the patient level (i.e., ecological 
fallacy). In addition, study-level meta-regression has limited 
sensitivity to detect important patient-level factors related 
to the outcome. To accurately derive these relationships, 
analysis of individual patient data (IPD) is needed.15–19 
Meta-analyses of IPD are considered the gold standard for 
systematic reviews.16,20
To address factors associated with placebo responses in 
neuropathic pain, we performed a meta-analysis of patient-
level data pertaining to six placebo-controlled randomized 
trials (RCTs) conducted in the field of SCI. Our primary 
aim was to examine the effect of subject-level predictors on 
placebo responses. Specifically, we tested the hypothesis that 
patient demographics, injury, and pain characteristics con-
tribute to the variability of placebo responses in individuals 
with neuropathic pain after SCI.
Materials and methods
This study was approved by the University of British Colum-
bia’s Clinical Research Ethics Board (H15-00475).
Study selection: search, inclusion, and 
exclusion criteria
A systematic literature search of English-language articles 
was performed using PubMed between September 2015 and 
January 2016. Search terms included “placebo”, “spinal cord 
injury”, and “pain”. Hand searching was also performed, 
reviewing reference lists of relevant trials and comprehensive 
review articles. Additional search terms and combinations 
were considered to further identify relevant studies (e.g., 
“neuropathic”, “central pain”). We included randomized, 
placebo-controlled, parallel- or crossover-designed studies for 
which IPD were available. Only datasets from  pharmacologic 
studies using inert placebos and treatment durations longer 
than 4 weeks were included in this analysis. Case studies and 
open-label clinical trials (i.e., those with no placebo condi-
tion) were excluded. Based on this search, corresponding 
authors were contacted by email to obtain the patient-level 
data. Contact was also made by email for industry-sponsored 
studies.
Predictor variables
The following patient-level information was obtained for 
all subjects undergoing placebo treatment: age, sex, injury 
characteristics (i.e., level and severity of injury, time 
since injury), and pain characteristics (i.e, baseline and 
post-placebo pain intensity, quality of pain (i.e, evoked). 
The level and severity of injury were classified using the 
International Standards for the Neurological Classification 
of SCI.21 Level of injury was dichotomized as thoracic or 
cervical. Completeness of injury was determined accord-
ing to the American Spinal Injury Association Impairment 
Scale (AIS) grades. Injury completeness was dichotomized 
as “complete” (i.e., AIS-A subjects, with no sensory or 
motor function caudal to the level of injury) or incomplete 
injuries (i.e., AIS-B to D subjects, with motor and/or sen-
sory sparing).21
Statistical analysis
R Statistical Software version 2.15.3 was used for all analy-
ses. Placebo response (dependent variable) was defined as 
the overall change in rating of the neuropathic pain intensity 
(i.e., based on 0–10 numeric rating scale) from baseline to 
the end of the study or the last measurement. As there is a 
known trial-design effect on placebo response12 and to enable 
direct comparison with the parallel-designed studies, only 
patients who received placebo in the first arm were included 
for the analysis. A priori studies from the same investigators 
using similar experimental design (e.g., crossover study) were 
pooled to increase sample size.22,23
In step 1, multivariable regression statistics were used 
to calculate effect sizes (beta coefficient) and a measure of 
variance (standard error [SE]). Subject characteristics (age 
and sex), injury characteristics (plegia, completeness, and 
duration since injury), and pain characteristics (baseline pain 
intensity rating) were modeled separately. In an exploratory 
analysis, the effects of evoked pain (i.e., allodynia) and loca-
tion of pain (i.e., at-level, below-level, or both) on the placebo 
response were independently examined.22–25
Step 2 of our analysis examined the overall effect size of 
subject, injury, and pain characteristics across studies (i.e., 
a pooled effect size). The R package metafor was used to 
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perform a meta-analysis on the regression coefficients derived 
from bivariable and multivariable regression  models.26 Forest 
plots were produced to visualize the results from the random-
effect models (R function: forest). Funnel plots were used 
to assess publication bias (R function: funnel). To assess 
publication bias by examining asymmetry in the funnel plots, 
the Egger test was used (R function: regtest).27
Results
Study selection and characteristics
The results of the study selection are presented in Figure 1. 
A total of six placebo-controlled studies met the inclusion 
criteria and were thus included in the analysis.22–24,28–30 The 
data of 276 chronic SCI patients were acquired from the 
authors of the original studies22–24,30 or industry sponsors.28,29 
Six patients from one study24 had to be excluded as not all 
of the information required for the present study was avail-
able in the dataset. Table 1 provides a detailed overview of 
all the studies included. Ten studies were excluded from the 
analysis because of the use of an active placebo (n=2),25,31 
a treatment duration <4 weeks (n=7),25,31–39 or no access to 
the IPD (n=1).39
Placebo response
Figure 2A illustrates the placebo responses for all studies 
reviewed (β=–0.622; SΕ=0.39; p=0.115). Overall, there was 
no significant placebo response. No significant publication 
bias was detected by Egger’s regression test for funnel plot 
asymmetry (p=0.674; Figure 2B).
Multivariable regression analyses
All results from the multivariable regression analyses are 
summarized in Table 2.
Meta-regression: patient, injury, and pain 
characteristics
Based on meta-regression statistics of individual patient-level 
data, sex (β=0.635; SE=0.262; p=0.016; Figure 3A) and 
baseline pain intensity rating (β=−0.146; SE=0.073; p=0.044; 
Figure 4) were associated with placebo responses. Males and 
higher baseline pain intensity ratings were associated with 
larger placebo responses. No significant publication bias was 
detected by Egger’s regression test for funnel plot asymmetry 
(sex: p=0.669, baseline pain: p=0.361, placebo response: 
p=0.673). Age (Figure 3B), injury severity (Figure 5A), level 
(Figure 5B), and duration (Figure 5C) did not significantly 
predict placebo responses.
Planned exploratory analysis
In two available trials, evoked pain (β=0.345; SE=1.086; 
p=0.751; Figure 6A) was not associated with placebo 
responses. Placebo responses were higher in individuals 
with below-level compared with below- and at-level neu-
ropathic pain (i.e., both) (Figure 6B). However, this effect 
was not observed after adjusting for baseline pain (β=0.065; 
SE=0.481; p=0.893; Figure 6C).
Discussion
Our study examined factors contributing to variable placebo 
responses in individuals with SCI neuropathic pain. For that 
purpose, IPD (n=276) derived from six randomized clinical 
trials were examined. Based on a patient-level meta-approach, 
sex and baseline pain intensity ratings were the only variables 
significantly associated with placebo responses. There was 
a trend toward larger placebo responses in individuals with 
incomplete injuries (versus complete); however, this effect 
was not consistent across examined trials. Other neuropathic 
pain, injury, or subject characteristics were not related to 
Figure 1 Flow diagram for the selection of randomized placebo-controlled trials.
Abbreviation: IPD, individual patient data.
9 studies excluded
Active placebo (n=2)
Treatment duration ≤ 4 weeks
(n=7)
121 studies excluded
Other languages (n=2)
Not relevant (n=73)
Reviews, secondary analysis
of data, or editorials (n=23)
Case studies (n=3)
Animal studies (n=4)
Nonpharmacologic
interventions (n=16)
Number of studies screened
for eligibility
PubMed search:
Number of studies for which
IPD were not provided
No access to individual
patient data (n=1)
Total studies included in
analysis of individual patient
data
Number of studies for
which IPD were sought
n=7
Studies considered
n=16
n=137
“spinal cord injury”,
“placebo”, “pain”
n=6
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Table 1 Details of reviewed studies
Study details Study 1 Study 2 Study 3 Study 4 Study 5 Study 6
Publication, author, year Finnerup et al,22 
2009a
Finnerup et al,23 
2002a
Siddall et al,29 
2006
Cardenas et al,28 
2013
Richards et al,24 
2015
Andresen et al,30  
2016
Study design Crossover Crossover Parallel Parallel Parallel Parallel
Intervention Levetiracetam Lamotrigine Pregabalin Pregabalin Venlafaxine XR Palmitoylethanolamide
Duration of placebo, days
Mean (SD) 29.4 (11.6) 61.1 (2.5) 61.9 (30.5) 171.6 (9.6) 81.8 (9.4) 82.3 (22.3)
Subject characteristics
Number 18 12 67 106 39 34
Sex, n (%)
Male 15 (83.3) 10 (83.3) 54 (80.6) 91 (85.8) 33 (84.6) 29 (85.3)
Female 3 (16.7) 2 (16.7) 13 (19.4) 15 (14.2) 6 (15.4) 5 (14.7)
Age, years
Mean (SD) 56.6 (10.9) 41.5 (10.7) 49.8 (14.2) 45.3 (14.0) 42.7 (11.1) 54.4 (11.2)
Injury characteristics
ASIA Impairment Scaleb, n (%)
A: Complete 6 (33.3) 5 (41.7) 34 (50.7) 57 (53.8) 23 (59.0) 10 (29.4)
B: Incomplete 1 (5.6) 1 (8.3) 7 (10.4) 10 (9.4) 6 (15.4) 3 (8.8)
C: Incomplete 1 (5.6) 2 (16.6) 7 (10.4) 7 (6.6) 5 (12.8) 9 (26.5)
D: Incomplete 10 (55.6) 4 (33.3) 19 (28.4) 32 (30.2) 5 (12.8) 12 (35.3)
Cause of SCI, n (%)
Violence (e.g., gunshot)
−
0 (0) 0 (0) 8 (7.5) 14 (35.9) 0 (0)
Accident (e.g., fall, vehicular)
−
8 (66.7) 59 (88.1) 81 (76.5) 21 (53.8) 22 (64.7)
Other
−
4 (33.3) 8 (11.9) 17 (16) 4 (10.3) 12 (35.3)
Time since injury, years
Mean (SD) 4.6 (4.1) 13.0 (9.5) 10.4 (9.8) 10.6 (10.3) 16.7 (13.0) 11.7 (11.1)
Plegia, n (%)
Paraplegia 10 (55.6) 7 (58.3) 38 (56.7) 56 (52.8) 15 (38.5) 20 (58.8)
Tetraplegia 18 (44.4) 5 (41.7) 29 (43.3) 50 (47.2) 24 (61.5) 14 (41.2)
Pain characteristics
Baseline pain score
Mean (SD)c 6.8 (1.3) 5.3 (1.7) 6.7 (1.4) 6.5 (1.4) 7.0 (1.8) 6.2 (1.1)
Location, n (%)
At level of SCI 1 (5.6) 2 (16.7)
−
25 (23.7)
−
7 (20.6)
Below level of SCI 6 (33.3) 5 (41.7)
−
53 (50.0)
−
14 (41.2)
Both 11 (61.1) 5 (41.7)
−
28 (26.3)
−
13 (38.2)
Notes: aAs there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in 
the first arm were included for the analysis. bAmerican Spinal Injury Association (ASIA) Impairment Scale: A, no sensory or motor function is preserved; B, sensory function 
is preserved below the level of the injury, but there is no motor function; C, sensory and motor functions are preserved below the neurologic level, and more than half of 
the key muscles below the neurologic level have a muscle grade of <3; D, sensory and motor functions are preserved below the neurologic level, and at least half of the key 
muscles below the neurologic level have a muscle grade of >3. cBaseline pain levels were assessed using a 11-point Numeric Rating Scale (0=no pain, 10=worst possible pain).
Abbreviation: SCI, spinal cord injury.
placebo responses. Overall, placebo responses among indi-
viduals with neuropathic pain due to SCI were small and 
difficult to predict at the subject level.
Low placebo response hallmarks SCI 
clinical trials
According to our meta-analysis, individuals with SCI and 
neuropathic pain have no significant placebo response in 
clinical trials testing pharmacologic interventions lasting 4 
weeks or longer. This finding is in agreement with the small 
effect we previously reported,12 but is in stark contrast to 
the majority of other chronic pain conditions.40–46 Emerging 
clinical trial data have further substantiated our observation 
of limited placebo response in SCI patients. In a recent trial 
demonstrating the efficacy of botulinum toxin type A (BTXA), 
fewer than 10% of SCI patients administered saline achieved 
a meaningful reduction in pain (i.e., >30%).47 Comparatively, 
approximately almost half of the patients with myofascial 
pain in a similarly designed BTXA clinical trial (i.e., also 
4 weeks in duration, parallel design) responded (i.e., >30% 
reduction in pain) to the administration of saline.48 In a BTXA 
clinical trial, large placebo responses are expected, given the 
invasiveness of the intervention compared with conventional 
pharmacologic studies.49,50
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While there was no overall significant placebo response, 
three trials demonstrated average reductions in pain inten-
sity ratings with placebo. The largest placebo response was 
reported in a recent trial conducted in the USA.24 Compara-
tively, the most recent trial conducted in Europe reported no 
discernible placebo response.30 Collectively, these observa-
tions correspond with findings that indicate that placebo 
responses are increasing in American neuropathic pain 
clinical trials.51 However, the high placebo response in the 
American trial24 should be interpreted with caution as the 
study was focused on depression, which may confound the 
results; the placebo response rate in depression consistently 
falls between 20% and 40% (e.g., improvement on the 
29-item modified Hamilton Depression Scale).52–55
The presence of damage in the CNS represents the most 
distinguishing physiologic/anatomical feature that could 
explain small placebo responses in individuals with SCI. 
In principle, damage in the spinal cord disrupts normal 
physiology involved in generating placebo analgesia, thereby 
reducing the capacity to experience placebo response.56–58 Our 
subject-level meta-analysis indicates a trend to this effect, 
namely, that individuals with more complete injuries tended 
to exhibit smaller placebo responses than individuals with 
incomplete injuries (Figure 7). Comparatively, level of injury 
(i.e., para versus tetra) had no discernible impact on placebo 
responses. The impact of injury severity on individual placebo 
responses was not, however, consistent enough across trials 
to yield an overall effect. A variable effect of injury severity 
on placebo responses may be related to a number of factors, 
including that a clinical measure of damage in the spinal cord 
(i.e., AIS grades) is insufficient to characterize the extent of 
pathology in spinal pathways involved in placebo analgesia. 
From a pragmatic perspective, injury completeness may only 
have a subtle effect, while other factors play a much larger 
role in placebo (e.g., expectation).5,59–62
Predictors of placebo response
Reductions in pain were predicted by baseline ratings, insofar 
as patients with higher ratings demonstrated larger placebo 
responses. This is consistent with the notion that enrollment 
in clinical trials occurs when pain intensity is at its peak, 
and that a follow-up measurement is biased to decrease 
(i.e., regression toward the mean).63 Our observations also 
indicate that male patients have larger placebo responses 
than females. With regard to sex-related differences, other 
studies have reported similar observations64–66 or no effect of 
sex.67 Caution interpreting the effect of sex is warranted on 
the basis that the vast majority of subjects examined herein 
were male, consistent with the typical demographics of SCI.68
If not related to damage in the spinal cord, what factors 
unique to SCI explain markedly low placebo responses (i.e., 
no significant response across all trials)? SCI neuropathic 
pain is commonly regarded as a chronic condition refractory 
to treatment.69,70 This, in turn, could decrease expectation of 
benefit and drive lower placebo responses.71 The unique com-
plexities of neuropathic pain, including that pain symptoms 
arise from other secondary health complications (e.g., infec-
tions, spasticity, and pressure ulcers to name a few), may also 
contribute to low placebo responses. Finally, all of the IPD 
included in our meta-analysis are all from preapproval trials 
Figure 2 Change in pain intensity in the placebo group for all studies. 
Notes: A negative mean difference indicates a reduction in pain score after placebo treatment. Funnel plot: standard error against mean change in pain intensity for the 
placebo group for all studies. *Finnerup 2002 and Finnerup 2009:22,23 cross-over designed studies. As there is a known trial-design effect on placebo response and to enable 
direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these 
two studies were pooled.
Mean difference
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Figure 3 Effect of patients’ characteristics on the placebo response. 
Notes: (A) Age had no modulatory effect on the placebo response. (B) There was a significant main effect of sex. That is, being male was associated with higher placebo 
response. A negative mean difference indicates a reduction in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009:22,23 cross-over designed studies. As 
there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first 
arm were included for the analysis. To increase the sample size these two studies were pooled.
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Figure 4 Effect of baseline pain intensity and duration of placebo treatment.
Notes: Higher baseline pain ratings at baseline were associated with greater placebo responses. A negative mean difference indicates a reduction in pain score after placebo 
treatment. *Finnerup 2002 and Finnerup 2009: cross-over designed studies.22,23 As there is a known trial-design effect on placebo response and to enable direct comparison 
with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were 
pooled.
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(i.e., none were performed after a drug had been approved for 
use in SCI neuropathic pain). Larger responses are associated 
with postapproval trials.72 Future studies trialing pregabalin 
(i.e., a drug now approved for use in SCI neuropathic pain) 
could expect larger placebo responses than reported here.
Figure 5 Effect of injury characteristics on the placebo response. 
Notes: The placebo response was not affected by (A) injury completeness, (B) type of plegia (i.e., para- or tetraplegia), and (C) duration of spinal cord injury (SCI). A negative 
mean difference indicates a reduction in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009:22,23 Cross-over designed studies. As there is a known trial-
design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for 
the analysis. To increase the sample size these two studies were pooled.
Abbreviation: SCI, spinal cord injury.
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Limitations of the study
There are some limitations of our analysis. The low number of 
trials limits the results of our IPD meta-analysis. Despite many 
advantages compared to conventional group-level meta-analy-
ses,15 individual patient-level meta-analysis will remain limited 
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Figure 6 Effect evoked pain and pain location of pain (i.e., at level, below level, or both) on the placebo response. 
Notes: A negative mean difference indicates a reduction in pain score after placebo treatment. (A) The presence of evoked pain had no modulatory effect on the placebo 
response. (B) No difference in placebo response was detected between patients with at-level pain and patients with below level pain or both. Patients with below pain 
exhibited higher placebo responses compared to those who had at- and below level pain (i.e., both). (C) However, this effect of location was diminished when adjusting for 
baseline pain rating. Thus, the effect was only related to the baseline pain being higher. *Finnerup 2002 and Finnerup 2009:22,23 Cross-over designed studies. As there is a 
known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were 
included for the analysis. To increase the sample size these two studies were pooled.
Abbreviation: RE, random effects.
Mean difference
At vs below
RE model
RE model
RE model
RE model
At vs both
Below vs both
0.35 (–1.78, 2.47)
–0.75 (–2.07, 0.57)
1.42 (0.15, 2.70)
–1.03 (–3.21, 1.15)
–0.31 (–0.66, 0.04)
–0.12 (–0.85, 0.62)
–1.05 (–3.25, 1.14)
–0.29 (–0.60, 0.02)
–0.91 (–1.16, –0.66)
–0.33 (–1.55, 0.89)
–0.25 (–1.85, 1.34)
–0.85 (–1.15, –0.55)
0.60 (–0.84, 2.03)
0.45 (–0.81, 1.70)
0.27 (–0.60, 1.14)
RE model
Andresen et al,30 2016
Cardenas et al,28 2013
Pooled crossover studies*
p=0.75
A
B
C
p=0.07
p=0.54
p<0.01
p=0.89
Effect of evoked pain
Effect of pain location
Effect of pain location
(adjusted for baseline pain)
Cardenas et al,28 2013
Pooled crossover studies*
Andresen et al,30 2016
Cardenas et al,28 2013
Pooled crossover studies*
Andresen et al,30 2016
Cardenas et al,28 2013
Pooled crossover studies*
0.59 (–0.85, 2.04)
0.48 (–0.78, 1.73)
–0.96 (–2.39, 0.48)
0.06 (–0.88, 1.01)
Andresen et al,30 2016
Cardenas et al,28 2013
Pooled crossover studies*
–2–3 –1 0 1 2 3
Mean difference
–3.5 –2.5 –1.5 –0.5 0.5 1.5 2.5
Mean difference
–3 –2 –1 0 1 2 3
by the inclusion of “accessible” study data. While accessibility 
is undoubtedly improving, open access data repositories with 
sufficient information to perform secondary data analyses are 
urgently needed.73 In addition to accessing data, important vari-
ables, such as a measure of expectation (e.g., whether a patient 
accurately predicted if they were in the placebo group), were 
not examined. As a surrogate of expectation, we did consider 
duration of injury. That duration had no effect on placebo 
responses may reflect that only chronic subjects were included 
(>4.6 years  postinjury on average, see Table 1). Future studies 
should aim to systematically address expectation in both the 
placebo and active treatment groups.59–62,74–76
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Figure 7 Effect of injury completeness on placebo response. 
Notes: There was a trend towards larger placebo responses in individuals with incomplete injuries (versus complete). A negative change in pain rating indicates a reduction 
in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009:22,23 Cross-over designed studies. As there is a known trial-design effect on placebo response and 
to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample 
size these two studies were pooled
Abbreviation: AIS, Association Impairment Scale.
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Conclusion
Our meta-analysis of IPD demonstrates that low placebo 
responses are a hallmark of neuropathic pain in RCTs of 
individuals with chronic SCI. Contrasting the hypothesis 
that disease-specific factors contribute to lower placebo 
responses, injury and pain characteristics were not predictive 
of changes in pain rating. All identified predictors – baseline 
pain and sex – are not disease-specific and, thus, poorly 
explain a reduced capacity to report placebo. These factors, 
however, still remain crucial to consider when designing 
clinical trials.
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